BMOV 是一种有效的胰岛素增敏剂，也是一种有效的、竞争性的、可逆的、口服具有活性的光谱蛋白酪氨酸磷酸酶 (PTP) 抑制剂。它抑制HCPTPA，PTP1B，HPTPβ和SHP2的IC50分别为 126 nM，109 nM，26 nM 和 201 nM。

BMOV is a potent, reversible, competitive and orally active pan-PTP (protein tyrosine phosphatases)inhibitor with insulin-mimicking effects and anti-diabetic properties. BMOV is a potent insulin sensitize. BMOV is shown to improve cardiac dysfunctions in diabetic models. BMOV inhibits HCPTPA, PTP1B, HPTPβ and SHP2 with IC50s of 126 nM, 109 nM, 26 nM and 201 nM, respectivelyr[1][2].

BMOV treatment enhances the phosphorylation of the insulin receptor and of the insulin signalling key intermediate Akt. BMOV treatment also resultes in an increased glucose uptake in C2C12 cells[1].

BMOV (0.75-3.0 mmol; intraperitoneal injection; twice weekly; for 6 weeks; Male C57BL/6J mice) treatment ameliorates the metabolic phenotype, as evidenced by reduced body weight, improved insulin sensitivity and glucose tolerance.

BMOV (0.75-3.0 mmol; intraperitoneal injection; twice weekly; for 6 weeks; Male C57BL/6J mice) treatment ameliorates the metabolic phenotype, as evidenced by reduced body weight, improved insulin sensitivity and glucose tolerance.

38213-69-3

C12H10O7V

317.15

Bis(maltolato)oxovanadium (IV);BMOV;双(麦芽醇)氧钒(IV);Bis maltolato oxovanadium,Bis(maltolato)oxovanadium (IV),bis maltolato oxo vanadium

DMSO:20 mg/mL (63.06 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years